Major Depressive Disorder Clinical Trials 2023

Browse 99 Major Depressive Disorder Medical Studies Across 274 Cities
15 Phase 3 Trial · 759 Major Depressive Disorder Clinics

Display Results

AllMost EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials Major Depressive Disorder Clinical Trials 2023

Reviewed by Michael Gill, B. Sc.

Image of Yale University in New Haven, United States.

Left Dorsolateral Prefrontal Cortex (L-DLPFC)for Borderline Personality Disorder

22 - 65

All Sexes

Stanford, CA

This trial looks at whether a new kind of brain stimulation called "aiTBS" can help people with borderline personality disorder who also have depression.

Recruiting

Device

Stanford HospitalNolan Williams, MD

Image of University of California, San Francisco in San Francisco, United States.

RTMS Therapyfor Major Depressive Disorder

18 - 70

All Sexes

San Francisco, CA

This trial is studying whether certain biomarkers can help predict treatment response to transcranial magnetic stimulation (TMS) in people with Major Depressive Disorder (MDD).

Recruiting

Has No Placebo

University of California, San FranciscoAndrew Krystal, MD, MS

Image of Advanced Research Center Inc in Anaheim, United States.

Seltorexantfor Major Depressive Disorder

18 - 74

All Sexes

Anaheim, CA

This trial is testing whether seltorexant can improve depressive symptoms in people with MDD who have had an inadequate response to current antidepressant therapy with an SSRI or SNRI. The trial will also assess the long-term safety and tolerability of seltorexant as adjunctive therapy to an antidepressant in people with MDD.

Advanced Research Center Inc (+38 Sites)Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC

Image of Grey Nuns Community Hospital in Edmonton, Canada.

Transcranial Direct Current Stimulationfor Transcranial Direct Current Stimulation

18+

All Sexes

Edmonton, Canada

This trial will test whether transcranial direct current stimulation is an effective treatment for ultra treatment-resistant depression.

Waitlist Available

Device

Grey Nuns Community HospitalSerdar M Dursun, MD, PhD

10 Major Depressive Disorder Clinical Trials Near Me

Top Hospitals for Major Depressive Disorder Clinical Trials

APG Research, LLC

Orlando

5Active Trials

5All Time Trials for Major Depressive Disorder

2018First Major Depressive Disorder Trial

University of Connecticut Health Center

Farmington

4Active Trials

9All Time Trials for Major Depressive Disorder

2003First Major Depressive Disorder Trial

Chicago Research Center

Chicago

4Active Trials

11All Time Trials for Major Depressive Disorder

2007First Major Depressive Disorder Trial

Baber Research Group

Naperville

4Active Trials

9All Time Trials for Major Depressive Disorder

2012First Major Depressive Disorder Trial

Lehigh Center for Clinical Research

Allentown

4Active Trials

24All Time Trials for Major Depressive Disorder

2006First Major Depressive Disorder Trial

Top Cities for Major Depressive Disorder Clinical Trials

Miami

23Active Trials

Pharmax Research Clinic IncTop Active Site

Dallas

15Active Trials

UT Southwestern Medical CenterTop Active Site

Major Depressive Disorder Clinical Trials by Phase of Trial

N/A Major Depressive Disorder Clinical Trials

25Active Major Depressive Disorder Clinical Trials

24Number of Unique Treatments

29Number of Active Locations

Major Depressive Disorder Clinical Trials by Age Group

< 18 Major Depressive Disorder Clinical Trials

4Active Major Depressive Disorder Clinical Trials

Seltorexant bupropion hydrobromide Cariprazine Active

Most Recent Major Depressive Disorder Clinical Trials

Clinical Trial

Began Recruiting Date

Phase

Esketamine for Major Depressive Disorder

9/13/2023

Phase 4

ketamine plus perampanel for Major Depressive Disorder

9/7/2023

Phase 1

High CBD [25:1] for Depression

8/28/2023

Phase 2

Omega-3 for Obesity

8/1/2023

Phase 2

Venlafaxine for Head and Neck Cancers

7/28/2023

Phase 4

Top Treatments for Major Depressive Disorder Clinical Trials

Treatment Name

Active Major Depressive Disorder Clinical Trials

All Time Trials for Major Depressive Disorder

First Recorded Major Depressive Disorder Trial

Ketamine

2006

Aticaprant

2022

Seltorexant

2020

Left Dorsolateral Prefrontal Cortex (L-DLPFC)

2021

Treatment

2005

Recently Completed Studies with FDA Approved Treatments for Major Depressive Disorder

Treatment

Year

Sponsor

ALTO-100 PO Tablet

2022

Alto Neuroscience

ALTO-100 PO tablet

2021

Alto Neuroscience

ALTO-300 PO tablet

2021

Alto Neuroscience

NBI-1065846

2021

Neurocrine Biosciences

Drug: CVL-354

2021

Cerevel Therapeutics, LLC

60 mg PRAX-114

2021

Praxis Precision Medicines

REL-1017

2021

Relmada Therapeutics, Inc.

PRAX-114

2021

Praxis Precision Medicines

REL-1017

2020

Relmada Therapeutics, Inc.

Antidepressant Medications

2020

Indiana University

About The Author

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: September 13th, 2023

References¹ Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4. https://pubmed.ncbi.nlm.nih.gov/10686270² George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46. https://pubmed.ncbi.nlm.nih.gov/20439832³ Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64. https://pubmed.ncbi.nlm.nih.gov/16894061⁴ Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382. https://pubmed.ncbi.nlm.nih.gov/444788⁵ Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4. doi: 10.1016/s0006-3223(99)00230-9. https://pubmed.ncbi.nlm.nih.gov/10686270⁶ Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. https://pubmed.ncbi.nlm.nih.gov/444788⁷ George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport. 1995 Oct 2;6(14):1853-6. doi: 10.1097/00001756-199510020-00008. https://pubmed.ncbi.nlm.nih.gov/8547583⁸ Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64. doi: 10.1001/archpsyc.63.8.856. https://pubmed.ncbi.nlm.nih.gov/16894061⁹ George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport. 1995 Oct 2;6(14):1853-6. https://pubmed.ncbi.nlm.nih.gov/8547583¹⁰ Pascual-Leone A, Rubio B, Pallardó F, Catalá MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. 1996 Jul 27;348(9022):233-7. https://pubmed.ncbi.nlm.nih.gov/8684201